Biomerica receives MHRA registration for hp+detect

Biomerica (BMRA) announced that it has received official registration from the UK Medicines & Healthcare products Regulatory Agency, MHRA, for its hp+detect diagnostic test that detects Helicobacter pylori bacteria. This product will now be marketed to labs throughout the UK for the detection of H. pylori infection in patients. “Receiving MHRA registration for hp+detect is a meaningful commercial milestone that expands our international reach into the United Kingdom,” said Zack Irani, CEO of Biomerica. “The UK represents an important addressable market given the high prevalence of H. pylori infection across Europe. This registration reflects our ongoing commitment to delivering innovative diagnostic solutions to patients and clinicians worldwide.”